JAMES HEALY - 08 Jun 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role: Director
Signature: /s/ Sune Reinholth Nyland, Attorney-in-Fact for James Healy
Issuer symbol: YMAB
Transactions as of: 08 Jun 2023
Transactions value $: $0
Form type: 4
Filing time: 09 Jun 2023, 18:00:54 UTC
Previous filing: 30 May 2023
Next filing: 14 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	YMAB	Common Stock	Award	$0	+2,330	+9%	$0	28,108	08 Jun 2023	Direct	F1
holding	YMAB	Common Stock						2,194,278	08 Jun 2023	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	YMAB	Employee Stock Option (right to buy)	Award	$0	+13,950		$0	13,950	08 Jun 2023	Common stock	13,950	$8.13	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date.
F2	The Reporting Person is one of the managing members of the general partner of Sofinnova Management X-A, L.L.C., the general partner of Sofinnova Management X, L.P., the general partner of Sofinnova Venture Partners X, L.P., which directly holds the reported securities, and, as such, may be deemed to share voting and investment power over such shares. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners X, L.P.
F3	Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F4	The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date, and are exercisable immediately upon vesting.